Cooperative Agreement U01FD008399
Award Date
9/5/24
Completion Date
8/31/28
Dollars Obligated
$1.3M
Funding Federal Agency
Office of Medical Products and Tobacco
Awarding Federal Agency
FDA Office of Acquisition and Grant Services
Federal Grant Program
93.103
Assistance Type
Cooperative Agreement
Place of Performance
Madison, WI 53715, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $801,476 to the University of Wisconsin System to study cerebrovascular reactivity as a biomarker for vascular contributions to cognitive impairment and dementia (VCID) in patients with CADASIL, a rare genetic form of stroke and VCID. Over the 5-year period from September 2024 to June 2029, the researchers will leverage an existing longitudinal cohort of 400 CADASIL patients and 100 healthy...
This $837,485 Cooperative Agreement awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) will fund a project to examine the effects of cadmium metal exposure and herpes viral infection on Alzheimer's disease-related genetic markers using human cerebral organoid models. Key objectives include: Performing RNA sequencing on the cerebral organoids to assess Alzheimer's-specific transcriptomic changes in response to cadmium exposure and/or herpes simplex virus-1 infection, and...
The National Institute on Aging (NIA) has awarded a $583,558 Project Grant (CFDA 93.866 - Aging Research) to the University of Alabama at Birmingham (UAB) to conduct research on the retinal manifestations of Alzheimer's disease (AD). The goal is to improve and simplify AD diagnosis by identifying early functional and molecular changes that precede cognitive decline and neurological damage. The project will pursue retinal testing in the APP/PS1 mouse model of AD, as well as in young, old,...
This federal Cooperative Agreement award from the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) supports the development of a qualification plan for the Virtual Reality Functional Capacity Assessment Tool-Short List (VRFCAT-SLX) as a performance outcome measure for assessing cognition-dependent daily functioning in people diagnosed with biomarker-positive, clinical stage 2 and 3 Alzheimer's disease (AD). The $249,984 award will fund a project...
This federal Project Grant awarded by the National Institute on Aging under CFDA 93.866 (Aging Research) aims to examine the role of specific phenotypes, such as sex/gender, APOE4 status, and polygenic hazard scores, on response to drug or lifestyle interventions in existing Alzheimer's disease clinical trials datasets. The $3,281,385 grant, awarded on September 1, 2024, will leverage data from 14,602 participants in 30 years of Alzheimer's clinical trials to analyze the impact of these...
The National Institute on Aging (NIA) awarded a $2,244,471 Project Grant under CFDA 93.866 (Aging Research) to Oregon Health & Science University (OHSU) to develop a first-in-class, CNS-penetrant small molecule agonist for G protein-coupled receptor 39 (GPR39) as a potential treatment for vascular cognitive impairment and dementia (VCID). The 3-year project from September 2023 to August 2026 will use in vitro and in vivo assays to identify lead compounds, determine their safety and...
The National Institute on Aging awarded a $4.6 million Project Grant to Cornell University under the Aging Research program (CFDA 93.866) to develop new imaging techniques for measuring microvascular blood flow in Alzheimer's disease and related dementia models. The award will support the design of an adaptive excitation source for 2-photon and 3-photon fluorescence microscopy to simultaneously measure blood flow speeds in approximately 300 cortical or 50 deep white matter microvessels. This...
This $715,539 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) to The Washington University in St. Louis aims to develop and evaluate a process for directly returning Alzheimer's disease (AD) biomarker research results to community-dwelling older adults. The study will create a culturally-appropriate protocol for communicating AD biomarker findings (Aim 1) and conduct a randomized trial to assess the safety and comprehension of directly sharing these...
This federal Project Grant award from the National Eye Institute (NEI), under the NIH's Vision Research program (CFDA 93.867), provides $603,488 to Versiti Wisconsin, Inc. to conduct research on the role of the signaling molecule Rap1B in regulating the balance between homeostasis and inflammation in retinal endothelial cells. The research aims to elucidate how Rap1B modulates the composition and organization of lipid rafts, which are critical for VEGF and TNF-α signaling, and how this in turn...
This $253,500 federal Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) will support the Icahn School of Medicine at Mount Sinai in reconstructing a human blood-retina barrier and perfused vascular system to investigate the role of APOE genetic variants in age-related macular degeneration (AMD). The project aims to leverage induced pluripotent stem cell technology to develop an in vitro model of the outer blood-retina barrier that can recapitulate AMD...